ADCs, including Adcentris® (Seattle Genetics) [86] and Kadcyla® (Genentech)[87], have received FDA approval for targeted treatment of relapsed Hodgkin Lymphoma and Her-2 positive breast cancer, respectively. The gene discussed is ERBB2; the disease is Hodgkins lymphoma.